Momenta Pharmaceuticals Inc., of Cambridge, Mass., said that in the wake of Tuesday's Supreme Court decision to remand a Copaxone (glatiramer acetate) patent infringement case (Teva Pharmaceuticals USA Inc. v. Sandoz Inc.) to the U.S. Court of Appeals for the Federal Circuit, it remained "optimistic" that an abbreviated new drug application for M356, a generic Copaxone it created with Sandoz Inc., "could be approved by the FDA in the near term."